等待開盤 10-07 09:30:00 美东时间
-2.625
-13.72%
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026. The board of directors appointed Warren Stone, currently president and chief operat...
今天 01:54
NeoGenomics (NEO) fell more than 12% on Tuesday, on track to record its worst one-day decline in over a year after the cancer diagnostics firm made a series of leadership changes and preannounced its ...
今天 01:37
受科技龙头上涨、美债收益率与油价双双下行的推动,美股股指期货周二走高。 截至发稿,道指期货涨0.71%,标普500指数期货涨0.50%,纳指期货涨0....
10-06 20:30
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Carlo Santarelli upgraded Boyd Gaming Corp (NYSE:BYD) from Hold to Buy and ...
10-06 20:07
BTIG analyst Mark Massaro upgrades NeoGenomics (NASDAQ:NEO) from Neutral to Buy and announces $28 price target.
10-06 18:04
NeoGenomics ( ($NEO) ) has issued an update. NeoGenomics said its board on Sept...
10-06 04:29
NeoGenomics (NEO) announced on Monday that it appointed Warren Stone as CEO and a board member, effective January 4, 2027. Current CEO Tony Zook will become executive chairman. Lynn Tetrault will ste...
10-06 04:13
NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that as part of a planned succession, its Board of Directors has appointed Warren Stone, current President and Chief Operating Officer ...
10-06 04:06
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual ...
08-27 04:20
今日重点评级关注:古根海姆:维持ProMIS Neurosciences"买入"评级,目标价从35美元升至69美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从38美元升至39美元
07-30 11:45